Skip to main content
Start triage

Start triage first, then route to emergency care.

Need urgent help? Start triage first, then route to emergency care.

Meds A-Z

Insulin

Detailed information about Insulin

Official label facts Owner quick guide first Marketing clearly labeled

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Add to My Pet's Meds

Choose a pet, confirm current or past, and optionally add reminder notes.

Sign in to save this medication to your pet profile.

Sign in to continue

Reviewed / Updated / Sources

Reviewed: Not available

Updated: February 12, 2026, 10:44 PM UTC

Sources:

Pet Owner Quick Guide

Start here first for the simple next-step summary.

Used for:

For the reduction of hyperglycemia and hyperglycemia-associated clinical signs in dogs with diabetes mellitus.

What to watch for:

  • Use of a syringe other than a U-40 syringe will result in incorrect dosing
  • For subcutaneous injection in cats only
  • Pancreatitis NOS (1 reports)
  • Other abnormal test result NOS (1 reports)
  • Not eating (1 reports)

When to call the vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
  • Facial swelling or hives.
  • Blood in vomit or stool.

Regulatory restrictions are shown in Vet View.

What to ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?
Safety & side effects

What to watch:

  • Use of a syringe other than a U-40 syringe will result in incorrect dosing
  • For subcutaneous injection in cats only
  • Pancreatitis NOS
  • Other abnormal test result NOS
  • Not eating

Most reported reactions:

  • Pancreatitis NOS (1 reports)
  • Other abnormal test result NOS (1 reports)
  • Not eating (1 reports)

When to call your vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.

Data freshness: source data appears current.

Latest refresh: Mar 21, 2026, 10:01 a.m.

Data freshness
  • Medication catalog: Source Roxee | Refreshed Feb 12, 2026, 10:44 PM UTC
  • Animal Drugs @ FDA: Source FDA | Refreshed Mar 21, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Mar 21, 2026, 10:01 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Mar 15, 2026, 10:05 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Feb 9, 2026, 3:22 AM UTC
Image coming soon
Insulin

Insulin

Drug type: Generic ingredient • Branded profile FDA branded products available

Species: Both

Manufacturer: Not available (source)

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: Not available
Form: Liquid (Suspension)
Identifiers:
NADA: 141236 NADA: 141297 NDC Package: 0010-4499-01 NDC Package: 0010-4499-02 NDC Package: 57926-490-62 NDC Package: 57926-490-69 NDC Product: 0010 NDC Product: 57926
Source metadata:

Warnings / Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use of a syringe other than a U-40 syringe will result in incorrect dosing. For subcutaneous injection in cats only.

  • High: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use of a syringe other than a U-40 syringe will result in incorrect dosing. For subcutaneous injection in cats only.
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
32
Serious reports
28
Species represented
2
Grouped by Body System
Digestive (3) · Vomiting, Diarrhea, Decreased appetite Neurologic (1) · Head tremor Other (28) · Pancreatitis NOS, Other abnormal test result NOS, Not eating
Most Reported Reactions
Reaction Body system Cases Species Serious cases
Other 1 Cat 1
Other 1 Cat 1
Other 1 Cat 1
Other 1 Dog 1
Other 1 Dog 1
Other 1 Cat 1
Other 1 Cat 1
Other 1 Dog 1

Species coverage: Cat (19) Dog (13)

View detailed reaction table
Reaction Body system Species Seriousness Frequency Reports
Digestive Cat Non-serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Non-serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Neurologic Dog Non-serious - 1
Other Cat Serious - 1
Other Dog Non-serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Digestive Cat Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Digestive Dog Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Source metadata:

Documents

Owner handouts and official technical documents are grouped for faster access.

Owner handout (Client Information Sheet)
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadLabeling/915
Owner handouts (1)
Official label / PI (3)
SPL (2)
  • Vetsulin® · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/283/Vetsulin%C2%AE
  • ProZinc® · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/2025/ProZinc%C2%AE
FOI (6)
  • UCM391560.pdf · FOI
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/781
  • UCM374300.pdf · FOI
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/780
  • ucm118049.pdf · FOI
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/779
  • ucm118048.pdf · FOI
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/778
  • FOI Summary sN 141-297 Approved February 8, 2019.pdf · FOI
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/6708
  • UCM198121.pdf · FOI
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/861
Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Medication catalog: Source Roxee | Refreshed Feb 12, 2026, 10:44 PM UTC
  • Animal Drugs @ FDA: Source FDA | Refreshed Mar 21, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Mar 21, 2026, 10:01 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Mar 15, 2026, 10:05 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Feb 9, 2026, 3:22 AM UTC
Official (FDA)
Identity: Generic ingredient • FDA branded products available
Official FDA brands: ProZinc® Vetsulin®
Case-reported brands (openFDA): MSK
Catalog species: Both FDA-labeled species: Cat, Dog
Rx/OTC: RX
Form/route: Liquid (Suspension) Subcutaneous
Applications: NADA 141-236 • NADA 141-297
Documents: 10 (FOI: 6) • SPL: 2 Label highlights Official documents
Safety (openFDA)
Top reactions: Dog 15 Cat 14 View
Case summaries: 10 (showing 8) View
openFDA reports are unverified and do not prove causation.

Explore
Linked using: Fda_Label (0.95), Fda_Label (0.95), Fda_Label (0.95)

Diagnosis Codes
ICD10_CM: E11.9
Type 2 diabetes mellitus without complications

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points
  • Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use of a syringe other than a U-40 syringe will result in incorrect dosing. For subcutaneous injection in cats only. (Contraindication, High)
Top reaction signals
Pancreatitis NOS (1) Other abnormal test result NOS (1) Not eating (1) Neutrophilia (1) Leucocytosis NOS (1) Ketosis (1) Ketonuria (1) Inappropriate urination (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
NADA: 141236 NADA: 141297 NDC Package: 0010-4499-01 NDC Package: 0010-4499-02 NDC Package: 57926-490-62 NDC Package: 57926-490-69 NDC Product: 0010 NDC Product: 57926
Package NDC Product NDC Form / Route Status
0010-4499-01 0010 -
0010-4499-02 0010 -
57926-490-62 57926 -
57926-490-69 57926 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 13 Clinical 0 Manufacturer 0 Marketing 0
Current Field Facts
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed v… (Official, 2026-02-12)
  • side_effects: Top reported reactions (openFDA): Hyperglycaemia, Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Diarrhoea, Weight loss, Hy… (Official, 2026-02-12)
  • usage: For the reduction of hyperglycemia and hyperglycemia-associated clinical signs in dogs with diabetes mellitus. For the reduction of hyperglycemia and hyperglyc… (Official, 2026-02-12)
Recent Revisions
  • side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
Vetsulin®
RX
Porcine insulin zinc suspension
Liquid (Suspension) Subcutaneous
Intervet, Inc. NADA 141-236 Approved Jul 1, 2024
ProZinc®
RX
Insulin
Liquid (Suspension) Subcutaneous
Boehringer lngelheim Animal Health USA, Inc. NADA 141-297 Approved Nov 13, 2023

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Species: Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied
Composition / specifications
Each mL of suspension contains 40 international units (IU) of insulin.
Dogs
Indication
For the reduction of hyperglycemia and hyperglycemia-associated clinical signs in dogs with diabetes mellitus.
Dosage
Administer an initial once-daily dose of 0.5 IU per kilogram of body weight by subcutaneous injection concurrently with or right after a meal. Adjust the once-daily dose described above at appropriate intervals based on clinical signs, urinalysis results, and glucose curve values until adequate glycemic control has been attained. Twice-daily therapy should be initiated if the duration of insulin action is determined to be inadequate. If twice-daily treatment is initiated, the two doses should be 25 percent less than the once daily dose required to attain an acceptable nadir.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Cats
Indication

For the reduction of hyperglycemia and hyperglycemia-associated clinical signs in cats with diabetes mellitus.

Dosage

Administer an initial dose of 1 to 2 IU by subcutaneous injection. Injections should be given twice daily at approximately 12-hour intervals. For cats fed twice daily, the injections should be concurrent with or right after a meal. For cats fed ad libitum, no change in feeding is needed. Adjust the dose at appropriate intervals based on clinical signs, urinalysis results, and glucose curve values until adequate glycemic control has been attained.

Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied
Composition / specifications
Each mL contains 40 international units (IU) insulin.
Cats
Indication
For the reduction of hyperglycemia and hyperglycemia-associated clinical signs in cats with diabetes mellitus.
Dosage
The initial recommended dose is 0.1 to 0.3 IU insulin/pound of body weight (0.2 to 0.7 IU/kg) every 12 hours. The dose should be given concurrently with or right after a meal.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use of a syringe other than a U-40 syringe will result in incorrect dosing. For subcutaneous injection in cats only.
Dogs
Indication

For the reduction of hyperglycemia and hyperglycemia-associated clinical signs in dogs with diabetes mellitus.

Dosage

Starting dose: The recommended starting dose for ProZinc® is 0.2-0.5 IU insulin/pound of body weight (0.5-1.0 IU/kg) once daily. The recommended starting dose for naïve dogs is the lower end of the dose range. The recommended starting dose for dogs with poorly controlled diabetes mellitus and transitioning from another insulin product is the mid to higher end of the dose range based on the veterinarian’s experience with the dog’s medical history and previous insulin dose. When transitioning from another insulin, the dog’s blood glucose and general condition should be closely monitored. When transitioning from another insulin, ProZinc® should be started once daily regardless of the frequency of prior insulin use.

The dose should be given concurrently with or right after a meal. The veterinarian should re-evaluate the dog at appropriate intervals and adjust the dose and frequency based on both clinical signs and laboratory test results (the blood glucose curve values and shape, nadir, and fructosamine) until adequate glycemic control has been attained. In the effectiveness field study, glycemic control was considered adequate if the glucose nadir from a 9-hour blood glucose curve was between 80 and 125 mg/dL, the maximum blood glucose was lessThanEqualTo 300 mg/dL, and clinical signs of hyperglycemia such as polyuria, polydipsia, or weight loss were improved.

Changing to twice daily dosing: Twice daily dosing should be considered if the duration of insulin action is determined to be inadequate with once daily dosing. Use caution when adjusting from once daily to twice daily dosing because ProZinc® may have prolonged duration of action in some dogs. The veterinarian should closely monitor the duration of action using blood glucose curves to avoid the increased risk of hypoglycemia. If twice daily dosing is initiated, the two doses should each be approximately 25% less than the once daily dose required to attain an acceptable glucose nadir. For example, if a dog receiving 10 units of ProZinc® once daily has an acceptable nadir but inadequate duration of activity, the dose should be changed to 7 units twice daily (round down to the nearest whole unit).

Further adjustments in the dosage may be necessary with changes in the dog’s diet, body weight, or concomitant medication, or if the dog develops concurrent infection, inflammation, neoplasia, or an additional endocrine or other medical disorder.

Limitations

FDA page: Open in Animal Drugs @ FDA

Official Documents (FDA)

Direct links to FDA-hosted PDFs and SPL packages (when available).

Documents
  • Summary
    The effect of the supplementis to add a 2.7 mL cartridge presentation for use with the VETPEN automatic injection device.
  • Summary
    The effect of the supplement is to change the specification for non-extractable (NE) insulin.
  • Summary
    This supplement provides for a new starting dose in dogs and for the use of VETSULIN in cats.
  • Summary
    For the reduction of hyperglycemia and hyperglycemia associated clinical signs with diabetes mellitus.
SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
SPL Packages

FDA page: Open in Animal Drugs @ FDA

Usage

For the reduction of hyperglycemia and hyperglycemia-associated clinical signs in dogs with diabetes mellitus. For the reduction of hyperglycemia and hyperglycemia-associated clinical signs in cats with diabetes mellitus.

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use of a syringe other than a U-40 syringe will result in incorrect dosing. For subcutaneous injection in cats only.

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive
Vomiting (1) • Cat Diarrhea (1) • Cat Decreased appetite (1) • Dog

Showing top 5 for Digestive.

Neurologic
Head tremor (1) • Dog

Showing top 5 for Neurologic.

Other
Pancreatitis NOS (1) • Cat Other abnormal test result NOS (1) • Cat Not eating (1) • Cat Neutrophilia (1) • Dog Leucocytosis NOS (1) • Dog
Show more (23)
Ketosis (1) • Cat Ketonuria (1) • Cat Inappropriate urination (1) • Dog Hypothermia (1) • Cat Hyponatremia (1) • Dog Hypokalaemia (1) • Cat Hypermetria (1) • Dog Hyperglycaemia (1) • Cat High blood pressure (1) • Dog Glucosuria (1) • Cat Excitation (1) • Dog Elevated total bilirubin (1) • Cat Elevated serum alkaline phosphatase (1) • Dog Elevated alanine aminotransferase (1) • Cat Dry mucous membrane (1) • Dog Distress (1) • Cat Digestive tract neoplasm NOS (1) • Cat Diabetic ketoacidosis (1) • Cat Dehydration (1) • Dog Decreased haematocrit (1) • Cat Death by euthanasia (1) • Cat Death (1) • Cat Collapse NOS (1) • Dog

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, ['Beagle', 'Terrier (unspecified)'], Female, 11 year, 21.772 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Head tremor, Hypermetria, Underdose • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2025-US-054757
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 11.00 Year
  • Weight: 21.772 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Head tremor Hypermetria Underdose
Outcomes: Recovered/Normal

Cat, Domestic Longhair, Female, 15 year, 4.3 kilogram • Drug: MSK, Unknown • Reactions: Ketosis, Death, Diabetic ketoacidosis, Unresponsive to stimuli • Outcome: Ongoing, Died

  • Report ID: USA-USFDACVM-2025-US-052696
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 15.00 Year
  • Weight: 4.300 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Ketosis Death Diabetic ketoacidosis Unresponsive to stimuli
Outcomes: Ongoing, Died

Cat, Domestic Shorthair, Female, 8.5 year, 3.31 kilogram • Drug: MSK, Unknown • Reactions: Vomiting, Hypothermia, Not eating, Elevated alanine aminotransferase, Hypokalaemia… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-052701
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 8.50 Year
  • Weight: 3.310 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Vomiting Hypothermia Not eating Elevated alanine aminotransferase Hypokalaemia Ketonuria Pancreatitis NOS Elevated total bilirubin Ketosis Decreased haematocrit
Outcomes: Ongoing

Cat, Manx, Male • Drug: MSK, Unknown • Reactions: Diarrhea, Digestive tract neoplasm NOS, Death by euthanasia • Outcome: Euthanized

  • Report ID: USA-USFDACVM-2025-US-052826
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Diarrhea Digestive tract neoplasm NOS Death by euthanasia
Outcomes: Euthanized

Dog, ['American Pit Bull Terrier', 'Dog (unknown)'], Male, 11.5 year, 29.1 kilogram • Drug: MSK, Subcutaneous • Reactions: Weight loss, Urinary tract infection, High blood pressure, Decreased appetite, Inappropriate urination… • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-052739
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 11.50 Year
  • Weight: 29.100 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Subcutaneous
Reactions Reported:
Weight loss Urinary tract infection High blood pressure Decreased appetite Inappropriate urination Dehydration Dry mucous membrane Systemic disorder NOS Hyperglycaemia Leucocytosis NOS Neutrophilia Elevated serum alkaline phosphatase Hyponatremia
Outcomes: Outcome Unknown

Cat, Domestic Mediumhair, Female, 11 year, 3.583 kilogram • Drug: MSK, Unknown • Reactions: Vomiting • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2025-US-072424
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 11.00 Year
  • Weight: 3.583 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Vomiting
Outcomes: Recovered/Normal

Cat, Domestic Shorthair, Female, 13 year, 4.9 kilogram • Drug: MSK, Unknown • Reactions: Other abnormal test result NOS, Weight loss, Glucosuria, Hyperglycaemia, Ketosis… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-049767
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 13.00 Year
  • Weight: 4.900 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Other abnormal test result NOS Weight loss Glucosuria Hyperglycaemia Ketosis Vomiting Distress
Outcomes: Ongoing

Dog, Dog (unknown), Female, 14 year, 17.3 kilogram • Drug: MSK • Reactions: Collapse NOS, Death • Outcome: Died

  • Report ID: USA-USFDACVM-2025-US-047097
  • Serious AE: Yes
  • Treated For AE: No
  • Sex: Female
  • Age: 14.00 Year
  • Weight: 17.300 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
Reactions Reported:
Collapse NOS Death
Outcomes: Died

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.